Can Pertuzumab be used during pregnancy?

Based on Pertuzumab's mechanism of action and animal studies, the drug can harm the developing fetus when given to pregnant women. There are no data on the use of this product in pregnant women; however, use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy has been associated with cases of oligohydramnios and oligohydramnios, manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Clinical factors need to be considered if this drug is used in combination with trastuzumab during pregnancy or within 7 months before conception.

Published data indicate that humanIgG is present in breast milk but does not enter the circulation of neonates and infants in significant amounts. Considering the developmental and health benefits of breastfeeding, as well as the mother's clinical need for pertuzumab therapy, and any potential adverse effects of pertuzumab or the underlying maternal disease on the breastfed child, advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of pertuzumab in combination with trastuzumab.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.